The FDA is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs. Each month, the administration approves numerous new therapeutics. We have summarized the FDA approvals for July below. You can use the hot links to learn more about the drugs.

FDA approves Fostemsavir (DB11796), a first-in-class attachment inhibitor for the treatment of multidrug resistant HIV-1 in patients with few viable options.

FDA approves INQOVI, the first oral product combining the nucleoside analogue Decitabine (DB01262) with the cytidine deaminase inhibitor Cedazuridine (DB15694) for the treatment of myelodysplastic syndromes (MDS).

FDA approves Abametapir (DB11932), a novel metalloproteinase inhibitor for the treatment of head lice.

FDA Approves Qwo (DB00048) (collagenase clostridium histolyticum), the first injectable treatment for cellulite.

FDA approves Brexucabtagene autoleucel (DB15699), an autologous modified T cell immunotherapy employing a CD19-directed chimeric antigen receptor for the treatment of relapsed and refractory mantle cell lymphoma.